KRAS and non-small cell lung carcinoma: This immune regulation function of KRAS-mutations may improve tumor cell survival in the brain, but it also makes NSCLC BMs with KRAS-mutations more susceptible to treatment with immune checkpoint inhibitors (ICIs) [88].